Cancer drug price cuts experts as patent therapies see zero relief, markups exceed benchmark | Today’s news

As a result, there has been no price reduction for several prohibitively expensive proprietary therapies. Prices remained unchanged Lung cancer treatments from AstraZeneca Osimertinib and Selumetinib, Pembrolizumab from MSD, Roche’s breast cancer combination Phesgo, Alecensa and Avastin, Daratumumab from Janssen, Gilteritinib from Astellas and Padcev, Johnson & Johnson from Johnson & Johnson, Rybrevant from Johnson & Johnson, Lorevant from Gsbrig from GssK Alunbri from Pfizer. and AbbVie’s Imbruvica.